Nanomedicine and drug delivery
6 European H2020 organizations list this as part of their work — 2 as their primary capability.
Most active in this area
- UNIVERSITEIT UTRECHT
Major Dutch research university with deep strengths in nanomedicine, life sciences, climate research, and sustainability policy across 346 H2020 projects.
“Projects like NABBA (nanoparticles overcoming biological barriers), DRIVE (diabetes-reversing implants), and multiple ERC grants on colloids, self-assembly, and biomaterials demonstrate sustained depth in nanoscale therapeutics.”
PrimaryNL346 projects - UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA
Italian research university strong in computational genomics, nanomedicine, and mathematical physics, with broad EU project leadership experience.
“Coordinated NABBA (nanoparticle drug delivery across biological barriers) and BIOINOHYB (bioinorganic hybrids for nanomedicine), with participation in related materials projects.”
PrimaryIT89 projects - ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
Milan-based pharmacological research institute specializing in kidney disease, toxicology, clinical trials, and epidemiology across 30 H2020 projects.
“Growing presence through NanoCarb (glyco-nanoparticles), LASER OPTIMAL (gold nanoparticle tumour ablation), MIMIC-KeY (extracellular vesicle-mimicking nanoparticles), and nPETS (nanoparticle health impacts).”
IT30 projects - University of Arkansas
US research university contributing specialized expertise in nanomedicine, cancer imaging AI, marine biotechnology, and paleoanthropology to European consortia.
“Partner in MEPHOS, working on mechano-pharmacological properties of microparticles for musculoskeletal disease treatment.”
US4 projects - ENVIROINVEST KORNYEZETVEDELMI ES BIOTECHNOLOGIAI ZARTKORUEN MUKODO RESZVENYTARASASAG
Hungarian biotech SME developing phage-based pest control, environmental monitoring solutions, and biotechnical water treatment technologies.
“NABBA project addressed nanoparticle-based drug delivery systems designed to overcome biological barriers.”
SMEHU3 projects - ETHERNA IMMUNOTHERAPIES
Belgian biotech developing therapeutic mRNA cancer vaccines using proprietary TriMix platform, with clinical-stage programs in HPV-related cancers.
“EXPERT covers lipid nanoparticles, extracellular vesicles, and drug targeting approaches for mRNA delivery.”
SMEBE3 projects